Study finds major gaps in cancer screening use in Federally Qualified Health Centers

NewsGuard 100/100 Score

A national study led by researchers at The University of Texas MD Anderson Cancer Center and The University of New Mexico (UNM) Comprehensive Cancer Center found major gaps in breast, cervical and colorectal cancer screening use in Federally Qualified Health Centers (FQHCs) in the U.S., relative to overall screening rates in the country.

The findings, published today in JAMA Internal Medicine, revealed screening use in FQHCs was 45.4% for breast cancer, 51% for cervical cancer and 40.2% for colorectal cancer, compared to cancer screening rates in the general American population of 78.2%, 82.9% and 72.3%, respectively.

FQHCs provide high-quality primary care to underserved communities in the U.S., which are disproportionately comprised of racial and ethnic minorities, people without health insurance, and those living below the poverty level. These findings highlight an urgent need to focus on scaling up evidence-based screenings in these populations to mitigate cancer disparities."

Jane Montealegre, Ph.D., study author, associate professor of Behavioral Science at MD Anderson

The U.S. Preventive Services Task Force (USPSTF) offers guidance for the general population to get screened for breast, cervical and colorectal cancer based on age and family history. However, screening use remains suboptimal in many marginalized populations. About 30 million people in the U.S. who might not otherwise have access to medical services currently use FQHCs.

The study, led by postdoctoral fellow Trisha Amboree, Ph.D., examined screening information from the Health Center Program Uniform Data System from 1,364 FQHCs between January 1 and December 31, 2020. To understand screening in the general population, researchers evaluated data from the Behavioral Risk Factor Surveillance System, which includes the use of preventive health services for non-institutionalized U.S. adults over the age of 18, during the same time period.

Researchers found cancer screening use in FQHCs varied widely across states. Certain states, such as Maine and New Hampshire, achieved screening rates over 60% and others fell below 35%, including Utah, Wyoming and Alabama. Additionally, the study revealed underscreened populations served by FQHCs in specific states contributed to a large proportion of America's overall underscreened population. Experts attribute these differences, in part, to the variability of state screening programs and policies around healthcare funding.

"FQHCs face financial constraints and staff turnover while trying to provide care in a fragmented health system. Implementing clinical preventive services such as cancer screenings will require additional support," said corresponding author Prajakta Adsul, M.B.B.S, Ph.D., assistant professor of Internal Medicine at UNM. "With investments in implementation research in FQHCs, there is potential to mitigate screening-related disparities in medically underserved populations."

Limitations of the study include self-reporting in the datasets and potential effects from the COVID-19 pandemic. 

The research was supported by the National Institutes of Health (R01MD013715, R01CA232888, R01CA256660).

Source:
Journal reference:

Amboree, T. L., et al. (2024). National Breast, Cervical, and Colorectal Cancer Screening Use in Federally Qualified Health Centers. JAMA Internal Medicine. doi.org/10.1001/jamainternmed.2024.0693.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer